- Home
- DAO vs ZYME Comparison
DAO vs ZYME Comparison
Compare DAO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAO
- ZYME
- Stock Information
- Founded
- DAO 2006
- ZYME 2003
- Country
- DAO China
- ZYME United States
- Employees
- DAO N/A
- ZYME N/A
- Industry
- DAO Other Consumer Services
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- DAO Real Estate
- ZYME Health Care
- Exchange
- DAO Nasdaq
- ZYME Nasdaq
- Market Cap
- DAO 884.4M
- ZYME 973.9M
- IPO Year
- DAO 2019
- ZYME 2017
- Fundamental
- Price
- DAO $7.07
- ZYME $13.88
- Analyst Decision
- DAO
- ZYME Buy
- Analyst Count
- DAO 0
- ZYME 6
- Target Price
- DAO N/A
- ZYME $19.17
- AVG Volume (30 Days)
- DAO 102.5K
- ZYME 565.8K
- Earning Date
- DAO 02-27-2025
- ZYME 03-05-2025
- Dividend Yield
- DAO N/A
- ZYME N/A
- EPS Growth
- DAO N/A
- ZYME N/A
- EPS
- DAO 0.07
- ZYME N/A
- Revenue
- DAO $822,103,071.00
- ZYME $62,199,000.00
- Revenue This Year
- DAO $10.00
- ZYME $21.53
- Revenue Next Year
- DAO $12.79
- ZYME N/A
- P/E Ratio
- DAO $106.71
- ZYME N/A
- Revenue Growth
- DAO 7.53
- ZYME N/A
- 52 Week Low
- DAO $2.86
- ZYME $7.97
- 52 Week High
- DAO $8.01
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- DAO 56.61
- ZYME 48.04
- Support Level
- DAO $6.41
- ZYME $12.80
- Resistance Level
- DAO $6.76
- ZYME $14.63
- Average True Range (ATR)
- DAO 0.32
- ZYME 0.85
- MACD
- DAO -0.08
- ZYME -0.04
- Stochastic Oscillator
- DAO 66.67
- ZYME 25.29
About DAO Youdao Inc. each representing one
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and Youdao Pocket Translator.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.